NASDAQ:COEP Coeptis Therapeutics (COEP) Stock Price, News & Analysis $0.30 +0.02 (+6.76%) (As of 08:39 AM ET) Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$0.26▼$0.3852-Week Range$0.23▼$1.58Volume2,022 shsAverage Volume361,125 shsMarket Capitalization$11.14 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Coeptis Therapeutics alerts: Email Address Coeptis Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside900.0% Upside$3.00 Price TargetShort InterestHealthy1.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.26) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector624th out of 879 stocksBiological Products, Except Diagnostic Industry100th out of 150 stocks 3.0 Analyst's Opinion Consensus RatingCoeptis Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCoeptis Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Coeptis Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.14% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently decreased by 42.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COEP. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for COEP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.49% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coeptis Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coeptis Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Coeptis Therapeutics Stock (NASDAQ:COEP)Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Read More COEP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COEP Stock News HeadlinesJune 20, 2024 | prnewswire.comCoeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingMay 30, 2024 | prnewswire.comCoeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 13, 2024 | msn.comCOEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024May 8, 2024 | prnewswire.comCoeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024May 2, 2024 | prnewswire.comCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingApril 24, 2024 | finance.yahoo.comDeverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid LeukemiaApril 2, 2024 | prnewswire.comCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 1, 2024 | investorplace.comCOEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023February 28, 2024 | investing.comCoeptis expands license for CAR technology to autoimmune diseasesFebruary 26, 2024 | finance.yahoo.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 26, 2024 | prnewswire.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 17, 2024 | morningstar.comCoeptis Therapeutics Holdings Inc Ordinary Shares COEPFebruary 7, 2024 | finance.yahoo.comCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsFebruary 2, 2024 | msn.comCoeptis Therapeutics Risks Nasdaq Delisting Over Bid PriceJanuary 4, 2024 | finance.yahoo.comCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024December 9, 2023 | benzinga.comCoeptis Therapeutics Stock (NASDAQ:COEP) Insider TradesSee More Headlines Receive COEP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/07/2024Next Earnings (Estimated)8/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:COEP CUSIPN/A CIK1759186 Webcoeptispharma.com Phone724-934-6467FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+967.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-479.38% Return on Assets-226.57% Debt Debt-to-Equity Ratio0.03 Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual Sales$80,000.00 Price / Sales130.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book2.16Miscellaneous Outstanding Shares37,120,000Free Float29,142,000Market Cap$10.43 million OptionableNot Optionable Beta-0.90 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. David Mehalick (Age 55)Co-Founder, Chairman of the Board, CEO & President Comp: $360kMs. Christine Elise Sheehy (Age 56)Co-Founder and VP of Compliance & Corporate Secretary Comp: $151kMr. Daniel Alexander Yerace (Age 41)Co-Founder, VP of Operations & Director Comp: $360kMr. Brian Cogley M.B.A. (Age 37)Chief Financial Officer Comp: $208kDr. Colleen Delaney M.D. (Age 56)M.Sc., CSO & Chief Medical Officer Comp: $360kKey CompetitorsBM TechnologiesNYSE:BMTXAtara BiotherapeuticsNASDAQ:ATRACurisNASDAQ:CRISCyclo TherapeuticsNASDAQ:CYTHIN8bioNASDAQ:INABView All CompetitorsInsidersTara DesilvaBought 2,266 shares on 1/12/2024Total: $1,314.28 ($0.58/share)Brian CogleyBought 5,000 shares on 1/10/2024Total: $3,350.00 ($0.67/share)David MehalickBought 20,004 shares on 1/8/2024Total: $13,202.64 ($0.66/share)Daniel Alexander YeraceBought 10,850 shares on 1/5/2024Total: $7,486.50 ($0.69/share)Gene SalkindBought 11,600 shares on 1/5/2024Total: $8,004.00 ($0.69/share)View All Insider Transactions COEP Stock Analysis - Frequently Asked Questions How have COEP shares performed this year? Coeptis Therapeutics' stock was trading at $0.7839 at the start of the year. Since then, COEP shares have decreased by 61.7% and is now trading at $0.30. View the best growth stocks for 2024 here. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) released its quarterly earnings results on Friday, May, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter. How do I buy shares of Coeptis Therapeutics? Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COEP) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
